ArticleFrontiers in oncology2022

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.

Yingbo Shao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.